Kovack Advisors Inc. Takes $96,000 Position in Nyxoah S.A. (NASDAQ:NYXH)

Kovack Advisors Inc. acquired a new position in shares of Nyxoah S.A. (NASDAQ:NYXH) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $96,000.

A number of other large investors have also bought and sold shares of NYXH. Iron Triangle Partners LP bought a new stake in shares of Nyxoah during the 1st quarter valued at $3,413,000. CVI Holdings LLC bought a new stake in shares of Nyxoah during the second quarter worth $1,292,000. Finally, Ikarian Capital LLC acquired a new stake in shares of Nyxoah in the 1st quarter valued at about $684,000.

Analyst Ratings Changes

Several analysts recently issued reports on NYXH shares. Oppenheimer dropped their target price on Nyxoah from $15.00 to $13.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. HC Wainwright cut their price objective on Nyxoah from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, October 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 target price on shares of Nyxoah in a report on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Nyxoah has a consensus rating of “Buy” and an average price target of $17.00.

Nyxoah Price Performance

Nyxoah stock opened at $8.22 on Friday. The firm has a market cap of $205.01 million, a PE ratio of -4.40 and a beta of 1.45. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.28 and a quick ratio of 4.95. The stock’s fifty day moving average price is $9.06 and its two-hundred day moving average price is $8.72. Nyxoah S.A. has a one year low of $4.00 and a one year high of $20.00.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.